Hologic Stock Fair Value – HOLOGIC Reports Record Q4 FY2023 Earnings of USD 945.3 Million and Net Income of USD 90.6 Million

November 20, 2023

🌥️Earnings Overview

HOLOGIC ($NASDAQ:HOLX) reported revenues of USD 945.3 million and net income of USD 90.6 million for the fourth quarter of FY2023, representing a 0.8% and 23.7% year-on-year decrease respectively, when compared to the same period in 2023.

Price History

On Thursday, HOLOGIC reported record earnings of USD 945.3 million for the fourth quarter of FY2023, a 23.7% increase from the same quarter the previous year. The news of HOLOGIC’s positive performance in Q4 FY2023 caused their stock to open at $68.3 on Thursday but close at $67.2 after the end of the day, a 1.6% decrease from its previous closing price. Despite this slight dip, analysts remain upbeat about the company’s performance and expect it to continue to post strong results over the next few quarters. Live Quote…

About the Company

  • HOLOGIC_Reports_Record_Q4_FY2023_Earnings_of_USD_945.3_Million_and_Net_Income_of_USD_90.6_Million”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Hologic. More…

    Total Revenues Net Income Net Margin
    4.03k 456 12.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Hologic. More…

    Operations Investing Financing
    1.05k -152.1 -483.2
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Hologic. More…

    Total Assets Total Liabilities Book Value Per Share
    9.14k 4.12k 21.16
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Hologic are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    2.2% -12.2% 19.5%
    FCF Margin ROE ROA
    22.4% 9.5% 5.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Hologic Stock Fair Value

    At GoodWhale, we recently conducted an analysis of HOLOGIC‘s financials. Our proprietary Valuation Line revealed that the intrinsic value of HOLOGIC share is around $63.8. This implies that investors might not be able to gain any significant returns from buying HOLOGIC stock at this current price. More…

  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    The company’s products are used in a variety of settings, including hospitals, clinics, and physician offices. Hologic also provides a range of services, including support, training, and education. The company has a strong presence in the United States and international markets, and its products are backed by a large body of scientific research. ALR Technologies Inc, G Medical Innovations Holdings Ltd, and Omega Diagnostics Group PLC are all competitors of Hologic Inc.

    – ALR Technologies Inc ($OTCPK:ALRT)

    ALR Technologies Inc is a publicly traded company with a market capitalization of $19.32 million as of 2022. The company has a return on equity of 17.26%. ALR Technologies is a leading provider of enterprise software solutions. The company’s products are used by organizations of all sizes to manage their businesses. ALR Technologies’ products are used by companies in a variety of industries, including healthcare, manufacturing, retail, and government.

    – G Medical Innovations Holdings Ltd ($NASDAQ:GMVD)

    As of 2022, Aetna’s market cap was 5.58M and its ROE was 783.79%. Aetna is a diversified healthcare benefits company that offers a broad range of traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities and health care management services for Medicaid plans.

    – Omega Diagnostics Group PLC ($LSE:ODX)

    Omega Diagnostics Group PLC is a medical diagnostics company. The company develops, manufactures, and supplies diagnostic test kits and instruments. It offers tests for the detection of allergies, food intolerances, infectious diseases, and hormones. The company sells its products through a network of distributors in the United Kingdom, Europe, the United States, Asia, Australia, and Africa.

    Summary

    HOLOGIC‘s fourth quarter FY2023 results showed a decrease in total revenue of 0.8% and net income of 23.7%, relative to the same period of the previous year. Despite the decline, analysts have pointed to the company’s strong balance sheet and low debt-to-equity ratio as reasons to remain bullish on the stock. Investors will be watching for improvements in gross margins, as well as a reduction in operating expenses as HOLOGIC works to reduce its reliance on volatile markets and return to healthy growth. With the company’s long-term prospects looking promising, investors may find HOLOGIC to be an attractive option in the current market environment.

    Recent Posts

    Leave a Comment